Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension

Cardiology. 2010;115(3):205-8. doi: 10.1159/000287638. Epub 2010 Feb 18.


Background: Pulmonary hypertension carries significant maternal and fetal risk during pregnancy and the postpartum period. As maternal mortality is high, specific targeted therapy for pulmonary hypertension may be required during pregnancy.

Cases: We describe 2 pregnant patients who presented with severe secondary pulmonary arterial hypertension during their last trimester. They were electively treated in the late antepartum and early postpartum periods with sildenafil and intravenous epoprostenol and successfully delivered healthy infants via cesarean section without postpartum complications.

Conclusion: Although pulmonary hypertension is associated with a risk of maternal mortality and most women are advised against pregnancy, new therapies may improve the outcome of pregnancy in patients with pulmonary hypertension.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cesarean Section
  • Drug Therapy, Combination
  • Epoprostenol / adverse effects
  • Epoprostenol / therapeutic use*
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Infant, Newborn
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Outcome*
  • Pregnancy Trimester, Third
  • Pulmonary Wedge Pressure / drug effects
  • Purines / adverse effects
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sterilization, Tubal
  • Sulfones / adverse effects
  • Sulfones / therapeutic use*
  • Vascular Resistance / drug effects
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*
  • Young Adult


  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Epoprostenol